{"Clinical Trial ID": "NCT01000662", "Intervention": ["INTERVENTION 1:", "ARM 1 Daily Boost", "Radiotherapy", "Radiotherapy: arms 1= 15 daily fractions of 2.7 Gy radiation, from Monday to Friday for 3 weeks, to the whole breast with concomitant daily stimulation of 0.5 Gy in tumour bed, for a total daily dose of 3.2 Gy in tumour bed (2.7 Gy+0.5 Gy). The overall dose will be 40.5 Gy in breast and 48.0 Gy in tumour bed.", "The arm 2= 15 fractions of daily radiation of 2.7 Gy from Monday to Friday for three weeks in the whole chest with a Friday increase of 2.0 Gy in tumour bed, for a total dose in tumour bed every Friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy in the breast and 46.5 Gy in tumour bed.", "INTERVENTION 2:", "ARM 2 Weekly Boost", "Radiotherapy", "Radiotherapy: arms 1= 15 daily fractions of 2.7 Gy radiation, from Monday to Friday for 3 weeks, to the whole breast with concomitant daily stimulation of 0.5 Gy in tumour bed, for a total daily dose of 3.2 Gy in tumour bed (2.7 Gy+0.5 Gy). The overall dose will be 40.5 Gy in breast and 48.0 Gy in tumour bed.", "The arm 2= 15 fractions of daily radiation of 2.7 Gy from Monday to Friday for three weeks in the whole chest with a Friday increase of 2.0 Gy in tumour bed, for a total dose in tumour bed every Friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy in the breast and 46.5 Gy in tumour bed."], "Eligibility": ["Incorporation criteria:", "Pre- and post-menopausal women with stage 0,I and II breast cancer", "Invasive breast cancer proven by biopsy, excised with negative margins of at least 1 mm", "\u2022 Situation after segmental mastectomy, after biopsy of the sentinel node and/or dissection of the axillary node (ICSD and tumours <5mm do not require nodal evaluation)", "At least 2 weeks after the last chemotherapy", "The patient must be able to understand and demonstrate his or her willingness to sign a written informed consent document.", "- Exclusion criteria:", "Previous radiotherapy in the ipsilateral breast", "More than 3 knots were identified at the axillary stage, requiring adjuvant axillary radiation", "- connective tissue disorders, such as lupus or sclerodermia", "Previous or concomitant malignancy other than basal or squamous skin cancer or cervical in-situ carcinoma, unless the disease exceeds 3 years", "Pregnant or lactating women"], "Results": ["Performance measures:", "Number of participants with acute toxicities recorded by radiotherapy oncology group (RTOG)", "Number of patients with Grade 2 or more toxicity after 3 weeks of whole breast MRRI with an increase once a week compared to patients treated with a daily increase: 0 - no symptoms, 5 - deaths directly related to radiation effects", "Calendar: Day 60", "Results 1:", "Title of the arm/group: ARM 1 Daily Boost", "Description of the arm/group: Radiotherapy", "Radiotherapy: arms 1= 15 daily fractions of 2.7 Gy radiation, from Monday to Friday for 3 weeks, to the whole breast with concomitant daily stimulation of 0.5 Gy in tumour bed, for a total daily dose of 3.2 Gy in tumour bed (2.7 Gy+0.5 Gy). The overall dose will be 40.5 Gy in breast and 48.0 Gy in tumour bed.", "The arm 2= 15 fractions of daily radiation of 2.7 Gy from Monday to Friday for three weeks in the whole chest with a Friday increase of 2.0 Gy in tumour bed, for a total dose in tumour bed every Friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy in the breast and 46.5 Gy in tumour bed.", "Total number of participants analysed: 202", "Type of measurement: Number", "Unit of measure: participants 22", "Results 2:", "Title of arm/group: ARM 2 Weekly Boost", "Description of the arm/group: Radiotherapy", "Radiotherapy: arms 1= 15 daily fractions of 2.7 Gy radiation, from Monday to Friday for 3 weeks, to the whole breast with concomitant daily stimulation of 0.5 Gy in tumour bed, for a total daily dose of 3.2 Gy in tumour bed (2.7 Gy+0.5 Gy). The overall dose will be 40.5 Gy in breast and 48.0 Gy in tumour bed.", "The arm 2= 15 fractions of daily radiation of 2.7 Gy from Monday to Friday for three weeks in the whole chest with a Friday increase of 2.0 Gy in tumour bed, for a total dose in tumour bed every Friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy in the breast and 46.5 Gy in tumour bed.", "Total number of participants analysed: 198", "Type of measurement: Number", "Unit of measurement: participants 16"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/202 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}